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Introduction: Understanding the mechanisms by which some individuals are able to naturally control HIV-1
infection is an important goal of AIDS research. We here describe the case of an HIV-1+ woman, CASE1, who has
spontaneously controlled her viremia for the last 14 of her 20 years of infection.
Methods: CASE1 has been clinically monitored since 1993. Detailed immunological, virological and histological
analyses were performed on samples obtained between 2009 and 2011.
Results: As for other Elite Controllers, CASE1 is characterized by low to undetectable levels of plasma HIV-1 RNA,
peripheral blood mononuclear cell (PBMC) associated HIV-1 DNA and reduced in vitro susceptibility of target cells to
HIV-1 infection. Furthermore, a slow rate of virus evolution was demonstrated in spite the lack of assumption of any
antiretroviral agent. CASE1 failed to transmit HIV-1 to either her sexual male partner or to her child born by vaginal
delivery. Normal values and ratios of T and B cells were observed, along with normal histology of the intestinal
mucosa. Attempts to isolate HIV-1 from her PBMC and gut-derived cells were unsuccessful, despite expression
of normal cell surface levels of CD4, CCRC5 and CXCR4. CASE1 did not produce detectable anti-HIV neutralizing
antibodies in her serum or genital mucosal fluid although she displayed potent T cell responses against HIV-1 Gag
and Nef. CASE1 also possessed multiple genetic polymorphisms, including HLA alleles (B*14, B*57, C*06 and
C*08.02) and HLA-C single nucleotide polymorphisms (SNPs, rs9264942 C/C and rs67384697 del/del), that have been
previously individually associated with spontaneous control of plasma viremia, maintenance of high CD4+ T cell
counts and delayed disease progression.
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Conclusions: CASE1 has controlled her HIV-1 viremia below the limit of detection in the absence of antiretroviral
therapy for more than 14 years and has not shown any sign of immunologic deterioration or disease progression.
Co-expression of multiple protective HLA alleles, HLA-C SNPs and strong T cell responses against HIV-1 proteins are
the most likely explanation of this very benign case of spontaneous control of HIV-1 disease progression.
Keywords: Human Immunodeficiency Virus (HIV), Viremia, Human Leukocyte Antigen (HLA), Single Nucleotide
Polymorphisms (SNPs), Elite controller (ELC), Long term nonprogressor (LTNP)Introduction
In the absence of combination antiretroviral therapy
(cART) HIV-1 infection results in AIDS and death in
most individuals. In contrast, a minority of individuals
demonstrate an almost absolute capacity to resist infec-
tion (e.g., carriers of CCR5-Δ32 homozygosity) [1].
Others, when infected, experience significantly delayed
disease progression, either in terms of maintenance of
peripheral CD4+ T cell counts ≥500 cells/μl after 7–8
years of HIV-1 infection (long-term non progressors,
LTNP) or by spontaneously controlling their HIV
viremia [commonly referred to as “Elite Controllers
(ELC)” when 90% of plasma HIV-1 RNA values are <50
copies/ml, or “HIV Controllers (HIC)”, when 90% of
plasma viremia measurements are <500 copies/ml for
≥12 months]. Rare (<1% of all infected individuals) cases
show both LTNP and EC features and have been defined
as “elite LTNP” [2,3].
Among other correlates of delayed HIV-1 progression
in the absence of cART the role of several alleles of
Human Leukocyte Antigen (HLA) Class I genes, such
as HLA-B*27 [4] and HLA-B*57 [5] has been well estab-
lished. Additional associations between MHC-Class I
and III SNPs and the LTNP phenotype have been ob-
served [6].
Thus, CASE1 detailed immunologic, virological and
genetic profile may provide clues to the design of thera-
peutic vaccines aiming at achieving a functional cure of
HIV-1 infection in the absence of ART [7].Methods
IRB approval
Biological samples were collected after receiving formal
written waiver from the institutional review board
(protocol MUCIM approved in January 2007 by the Eth-
ics Committee Ospedale San Raffaele, Milan, Italy), and
signed written informed consent.HIV-1 RNA and DNA quantitation
HIV-1 plasma RNA was measured using the Amplicor
Monitor (Roche) assay (dynamic range: 50–750,000 cop-
ies/mL), and HIV-1 DNA quantification was performed
using an in-house real-time PCR assay, as described [8].Viral genetic analysis
Isolation of plasma HIV RNA and PBMC-associated
HIV DNA, reverse transcription, amplification, gag and
env sequencing were performed according to the pub-
lished methods reported in the Additional file 1 section.
MiR-148a/b binding site (single nucleotide
polymorphisms, SNP: rs67384697) and -35Kb 5′UTR HLA-C
(SNP: rs9264942) analysis
Genomic DNA was extracted from CASE1’s PBMC
using the PureLink Genomic DNA kit (Invitrogen, Carls-
bad, CA), and a pyrosequencing approach was used to
determine SNPs. Detailed methods are reported in the
Additional file 1 section.
Culture and co-culture of rectal biopsy with allogeneic T
cell blasts
Histocultures of intestinal biopsies were performed as pre-
viously reported [9]; both cells and histoculture superna-
tants were collected 24 h later. Cells were dispersed by
enzymatic digestion with collagenase IV (0.5 mg/ml in
complete culture medium, 30 min at 37°C), passed through
a 22G needle and filtered with a 70 μm cell strainer. The
digestion was repeated and cells from the two rounds were
pooled and debris removed by centrifugation. Two million
biopsy-derived cells were cultivated either alone or with
2x10 [6] PHA-stimulated PBMC from two different donors
that had been previously depleted or not of CD8+ T cells
by magnetic immunobeads. Both cultures and co-cultures
were maintained for 30 days in IL-2 enriched medium, col-
lecting their supernatants every 3 days for measurement of
virus using either Mg++-dependent reverse transcriptase
(RT) activity [10] or HIV-1 p24 Gag antigen by ELISA.
HIV-1 isolation from and ex-vivo infection of CASE1 PBMC
Three independent attempts were made to isolate HIV-1
from peripheral CD4+ T cells according to published
protocols [11]. Supernatants were collected every 3–4
days for up to 4 weeks of cultivation and tested for the
presence of either Mg++-dependent reverse transcriptase
(RT) activity or HIV-1 p24 Gag antigen by ELISA.
For ex-vivo infection, CD4+ leukocytes from both
CASE1 and her partner were isolated by negative selec-
tion from peripheral blood by Ficoll-Hypaque, washed
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scribed above. Cells were stimulated with PHA and
3 days later washed and infected with CCR5-dependent
(R5) HIV-1BaL or CXCR4-dependent (X4) HIV-1LAI/IIIB
at a multiplicity of infection of 0.2. Culture supernatants
were collected every 3–4 days for up to 4 weeks and
tested for the presence of RT activity.
ELISpot assay for IFN-γ
Peptides
The Variable Overlapping Peptide Scanning Design
(VOPSD) technique [12] was used to design peptides
derived from HIV-1 encoded antigens Tat (11 peptides, Re-
pository number: ARP7103.1-11), Nef (30 peptides, Reposi-
tory number: ARP7102.1-30) and Gag (84 peptides,
Repository number: ARP7114.1-84) kindly provided by the
Centre for AIDS Reagents, National Institute for Biological
Standards and Control (NIBSC HPA UK). Single peptides
or peptide pools were used to stimulate PBMC collected in
November 2009 and June 2011 at a final concentration of
2 μM. Validation of the VOPSD strategy was obtained by
direct comparison with 15mer or 20mer peptide sets, as re-
cently reported [12]. ELISpot for IFN-γ was performed as
previously described [13], and detailed methods reported in
the Additional file 1 section.
Intracellular cytokine staining
Thawed PBMC (≥80% viable) were plated in a 96-well
plate after 4 h of resting (EuroClone) at a concentration of
1x10 [6] PBMC/well in complete RPMI medium [10% FBS
(Lonza-BioWhittaker) in RPMI (Lonza-BioWhittaker)]
with single/pools of HIV-1 derived peptides (2 μM) in
the presence of a mixture of co-stimulatory anti-CD28
and anti-CD49d Ab (1.3 μg/ml each, Becton Dickinson).
Cells were then treated and stained as previously de-
scribed [13]. Detailed methods are reported in the Add-
itional file 1 section.
Results
Clinical history
A previous female intravenous-drug user, (CASE1), was
diagnosed with HIV-1 infection in 1993 (age: 23 years
old) in the course of a pregnancy screening test; she was
confirmed to be HIV-1+ in the following years. CASE1
was repeatedly found seropositive for anti-HIV-1 anti-
bodies (Ab), but negative for anti-HIV-2 Ab. Her viremia
levels were undetectable when assessed for the first time
in May 1997, but 1,900 copies of HIV-1 RNA/ml were
demonstrated in Nov 1997 that dropped to 200 copies/
ml in Aug 1999. Since then, HIV-1 viremia levels, that
were monitored at least twice a year, have remained <50
copies/ml although CASE1 never assumed any antiretro-
viral agent. She also never reported clinical episodes sug-
gestive of immunodeficiency, while her peripheral CD4+and CD8+ T cell counts have remained in the normal
range of uninfected healthy individuals through all these
years (Figure 1A).
CASE1 reported >20 years of unprotected sexual inter-
course with her male partner, who remained HIV-1 sero-
negative. She also had a child born in 1994 by vaginal
delivery who has remained uninfected.
In 1997 CASE1 was diagnosed with hepatitis C virus
(HCV, genotype 3a) infection, becoming negative for HCV
viremia with normal levels of transaminases in 2005 after
therapy with Pegylated Interferon plus Rebetol (Additional
file 1: Figure S1).
Virological determinations and ex vivo infection of CASE1
CD4+ T cells
In June 2009 colon biopsies were taken for diagnostic
purposes. Hematoxylin-eosin, Giemsa, PAS staining and
transmission electron microscopy revealed normal hist-
ology of the intestinal mucosa, lack of inflammatory
infiltrates, microbes, virions or cell injury (Additional
file 1: Figure S2). The tissue was also negative for the
presence of HIV-1 p24 Gag+ cells by immunohistochem-
istry, although its viral DNA content was estimated to
be 881 copies/106 cells. In vitro cultivation of either 6
colon biopsy histocultures or of colon-derived leukocytes
(2x106 cells) co-cultivated with CD8-depleted T cell
blasts of two seronegative donors were negative for virus
replication in terms of either RT activity or p24 Gag pro-
duction (data not shown). Furthermore, neither allogen-
eic cultivation of 5x105 PBMC-purified CD4+ cells from
CASE1 with T cell blasts of two seronegative donors,
nor direct cultivation of the same number of CASE1
cells in medium containing IL-2, induced virus replica-
tion (data not shown).
Ex vivo infection of CASE1 CD4+ T cell blasts with
HIV-1 R5BaL or X4LAI/IIIB strains resulted in virus repli-
cation, although at lower levels compared to those ob-
served after infection of CD4+ T cell blasts from her
partner (Figure 1B and C).
Sequence analysis of CASE 1 HIV-1 DNA
Quantitative PCR from CASE1 plasma samples were re-
peatedly <50 copies HIV-1 RNA/ml (Figure 1A), and
only 2 viral genomes were detected in a total of 9 mL of
plasma from June and Nov 2009 by multiplex PCR to
amplify both full length gag and gp120 env coding se-
quences (see Additional file 1). Her PBMC-associated
HIV-1 DNA load in June, and Nov 2009 and in June
2011 was 28, <13 and 10 copies/106 cells, respectively.
In the same dates, 23 gag- and 20 gp120 env- sequences
(all with open reading frames) were obtained from a
total of 21x106 PBMC.
All 15 PBMC-derived single genome HIV-1 gag coding
sequences from June (N = 6) and Nov (N = 9) 2009 were
Figure 1 CASE1’s natural control of HIV-1 viremia. (A) Levels of peripheral CD4+ and CD8+ T cells, plasma viral RNA and the presence of
anti-HIV-1 Ab in CASE1 plasma were monitored over 20 years of infection. Purified peripheral CD4+ cells were isolated from CASE1 and infected
with either an R5 (B) or an X4 (C) strain, resulting in detectable virus replication. Purified CD4+ T cells of her sexual partner supported higher
levels of virus replication. Bars indicate error of the mean from duplicate cultures.
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(Figure 2A). In the case of env (Figure 2B), all 4 PBMC
sequences from June 2009 were identical; all 10 se-
quences from Nov 2009 encoded identical proteins (4
sequences had the same synonymous site mutation) and
differed from the June 2009 population at only one
amino acid. Three out of 6 env sequences from June 2011
were identical to the major Nov 2009 population and 2
out of 6 were identical to the minor Nov 2009 population.
One env sequence and gag sequences from 3 June 2011
were subtle outliers, with an additional 5 or 5–17 changes,
respectively, relative to the major virus populations
(Figure 2). Despite this exceptional overall homogeneity in
cell-associated viral DNA (Mean sequence diversity acrossall 3 time points =0.17% in gag and 0.08% in env), the sin-
gle gag and env sequences obtained from the Nov 2009
plasma sample were significantly divergent from the
PBMC-associated DNA sequences (Mean =1.1% in gag
and 2.5% in env), although they each shared some of the
mutations that distinguished the PBMC outlier se-
quences from Nov2011. The changes in gag shared with
each of the outlier PBMC led to the reversion of the
B*57-associated AA substitution I147L in the immuno-
dominant [14] B*57 epitope IW9, restoring the optimal
CTL epitope sequence, and to the introduction of the
T242N substitution in the TW10 epitope (Figure 2A),
normally associated with CTL escape. No mutations
were observed in the B*57-restricted epitopes KF11 or
Figure 2 Phylogenetic analysis of CASE1 HIV-1 gag and env sequences. Viral genome templates corresponding to the near full length gag
gene (HXB2 nucleotides 818–2276) and the gp120 coding region of env (HXB2 nucleotides 6229–7786) were PCR amplified from blood plasma
and PBMC DNA collected in June and November of 2009, and from PBMC from June 2011, as described in Additional data. PCR products derived
from individual viral templates were sequenced directly and analyzed as described in Additional data. PBMC- and plasma (PL)-derived sequences
are labeled by date (YYMMDD). Mutations at specific tree branches are tallied as either non-synonymous (NS) or synonymous (S). Two epitopes
changed over time in gag (A). The B*57 associated AA substitution I147L in the immunodominant B*57 epitope IW9 was a reversion mutation,
resulting in a susceptible, consensus form of the epitope - hence the branch extends from the CASE1 sequences earlier in infection towards the
consensus. The TW10 mutation, by contrast, was an escape mutation, with the consensus of all of the Group M viruses being the susceptible form
of the epitope - hence the branch extends from the CASE1 sequences earlier in infection away from the consensus. These 2 NS mutations are
bolded and noted by a thick arrow between the sequences. NS mutations resulting in two potential N-linked glycosylation sites (PNLGS) were
found in env (B). The scale bar below each dendrogram illustrates the branch length formed by mutations corresponding to a 1% change. Amino
acid alignments are provided in Additional data.
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nally, 2 of the 3 shared non-synonymous site changes in
env corresponded to acquisition of potential N-linked
glycosylation sites (Figure 2B).
CASE1 protective alleles
Although not carrying the protective alleles CCR5-Δ32
and CCR2-64I, CASE1 does express HLA B and C al-
leles (B*14.02 and B*57.08; C*06 and C*08.02), previ-
ously associated, either alone [5,15] or in combination
[16,17], with slow/non-progression in LTNP and low
levels of viremia in the absence of cART assumption.In addition, CASE1 possesses the C/C genotype in the
rs9264942 (C/T) -35 SNP and the del/del polymorphism
(rs67384697 G/deletion) mapping upstream to the 5′
and within the 3′ untranslated region of the HLA-C
gene, respectively. These 2 SNPs have been reported to
be in strong linkage dysequilibrium being associated
with control of HIV-1 viremia [5,6].
Immunological phenotypes and immune responses
CASE1 and her partner were found to have a distribution
of B lymphocyte subpopulations comparable to those of
uninfected individuals (Additional file 1: Table S1). Two
Figure 3 (See legend on next page.)
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Figure 3 T-cell responses of CASE1 T cells to Gag, Nef, and Tat peptides. (A) Recognition of Gag and Nef, but not of Tat peptide pools by
CASE1 PBMC collected in June 2011. (B) Recognition of Gag pools (A-L): pools D, E, G, H, and I contain well-defined HLA-B*57 restricted Gag
epitopes. (C) Identification of epitopes recognized by CASE1 contained in Gag pools D, E, H and I. The table provides the HLA-restriction, the
peptide designation and its sequence. The sequence of minimal epitopes for both Gag and Nef are shown in bold. (D) PBMC isolated from
CASE1 were either left unstimulated or were stimulated with Gag peptide #25 and #26 and functionality of CD8+ T assessed by means of
cytofluorimetric analysis for the production of Granzyme-B (GzB), Interferon-γ (IFN-γ), CC chemokine ligand 4 (CCL4)/Macrophage Inflammatory
Protein-1β (MIP-1β) and Tumor Necrosis Factor-α (TNF-α); the cell population was subdivided into the CD45RA+ and CD45RAneg CD8+ T-cell
subsets and the percentages of these subsets were calculated relative to the peptide 25 and 26 Gag-specific response. (E) Recognition of Nef
overlapping peptides. The HLA-B*57 and C*06 restricted minimal epitopes contained in Nef #13 (RPMTYKAAVDLSHFLK) were: RPMTYKAAV
(C*06), MTYKAAVDL (C*06), KAAVDLSHF (B*57), AAVDLSHFL (C*06); minimal epitopes in Nef #18 (LDLWIYHTQGYFPDWQNY) and Nef #19
(YHTQGYFPDWQNYT) were: HTQGYFPDW (B*57) and GYFPDWQNY (C*06). The dotted line indicates the negative cut-off of the assay.
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lins) and cervico-vaginal derived Ab collected in June
2009 and Nov 2009 did not show neutralizing activity
against a panel of different HIV clades and phenotypes
(Additional file 1: Table S2). CASE1 and her partner
also had a normal distribution of T cell subpopulations
(Additional file 1: Table S3), and both expressed com-
parable levels of CXCR4 and CCR5 on CD4+ lympho-
cytes (Additional file 1: Figure S4).
The breadth and magnitude of T-cell responses were
assessed using CASE1 PBMC collected in Nov 2009 and
June 2011. T cell responses were observed against Gag
and Nef but not against Tat peptides (Figure 3A). Recog-
nition of Gag peptide pools was mainly directed against
regions containing well-defined HLA-B*57-restricted
Gag epitopes (pools D, E, G, H and I, Figure 3B), with-
out appreciable differences between the two dates.
Among the peptides present in Gag pools D and E,
those expressing HLA-B*57 restricted epitopes (I/LW9
peptides 25 and 26 from pool D; KF11 peptide 29 and 30
pool E) mounted the strongest T-cell response (Figure 3C)
as reported for LTNP [18]. Interestingly, recognition of
the B*14-restricted epitope DA9, previously associated
with virological control [19], was also observed (peptides
52 and 53 from pool H), whereas recognition of the B57*
restricted epitope QW9 (peptide 54 and 55) was absent
(Figure 3C). Moreover, recognition of pool I was not di-
rected against the B*57-restricted epitope TW10 (peptides
42 and 43), but toward the C*06 restricted epitope KL9
(peptide 59, Figure 3C).
Among CD8+ T cells specific for HLA-B*57 (I/L)W9
restricted Gag epitopes (peptides 25 and 26), 34.6%
expressed CCL4/MIP-1β and 50.5% were polyfunctional
(Figure 3D). Recognition of Nef peptide pools was also
mainly directed against regions containing well-defined
HLA-B*57 and C*06 restricted Nef epitopes (Figure 3E).
Conclusions
We here report that a woman (CASE1), who has been
infected with HIV-1 for at least 20 years, has remained
in good health with features of both EC and LTNP forthe last 14 years. CASE1 co-expresses HLA-B (*14 and
*57) alleles and HLA-B-mediated immune responses, to-
gether with HLA-C alleles (*06 and *08.02) associated
with SNPs rs9264942C/C and rs67384697G/deletion and
HLA-C restricted immune responses as her most evi-
dent features compatible with strong and durable con-
trol of HIV-1 infection and disease progression.
Although CASE1’s CD4+ T cells were infectable in vitro
by both R5 and X4 HIV-1 strains, they showed lower
levels of virus replication in comparison to those of the
seronegative partner, suggesting the presence of restriction
factors, such as p21 [20], limiting the virus replicative cap-
acity in vitro and perhaps accounting for the lack of virus
replication observed both in vivo and upon ex vivo cultiva-
tion of CASE1’s PBMC and gut-associated leukocytes.
Cell-associated HIV-1 DNA was detectable in PBMC
and gut-mucosa derived cells at very low levels while gag
sequences from single copy plasma RNA molecules and
PBMC-associated HIV-1 DNA revealed the late emer-
gence of mutations in two immunodominant HLA-B*57-
restricted Gag epitopes co-existing on the same sequences.
The mutation T242N observed in the TW10 epitope typ-
ically emerges early in infection and is known to effect
CTL escape and impair viral fitness. However, this muta-
tion is has not been associated with the EC status, being
more frequently detected in B*57+ HIV-1 progressors [21].
The second mutation emerged in the I/LW9 B*57 associ-
ated epitope, restoring the original IW9 epitope with little
or no impact on viral escape or fitness reported in prior
studies. This behavior is reminiscent of EC who have ex-
tremely low levels of viral RNA in plasma, significant dif-
ferences between contemporary viruses in the plasma and
PBMC, and a high frequency of synonymous mutations in
the plasma virus [22-25]. It is also noteworthy that HLA-
B*57 epitope variation emerged in plasma-associated virus
at the same sampling times of acquisition of two potential
N-linked glycosylation sites in Env, including one that was
previously implicated in the evasion of Ab neutralization
[26]. These viral features, together with the persistence of
CD8-mediated T cell responses, suggest the persistence of
extremely low levels of virus replication in CASE1. The
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in plasma-associated virus and in PBMC, in 2009 and
2011, respectively, suggests that her virological control
may be waning.
In addition, CASE1 carries a unique combination of
HLA-B protective alleles associated with CD8+ T cell-
mediated control of HIV-1 replication and strong CD8+
T cells polyfunctional responses against HLA-B*57 and
B*14-restricted Gag epitopes, as also observed in ELC
and LTNP [27] that may account for the lack of CD4+ T
cell depletion in peripheral blood and gut [28]. The
higher levels of expression of HLA-C alleles carrying a
deleted miR-148a/b binding site vs. those without a de-
leted site might facilitate greater T-cell recognition of in-
fected cells [29]. In support of this interpretation CASE1
was also characterized by the presence of long lasting
C*06-restricted T-cell responses against Nef epitopes.
HLA molecules play a central role in the control of
HIV disease progression [17]. In this regard, CASE1 has
multiple HLA features that were previously individually
associated with control of HIV-1 viremia, including
HLA class I alleles (HLA-B*057 and *014, HLA-C*06
and *0802) and two SNPs within the HLA-C locus
(rs9264942C/C, and 263 del/del, 259 T/T, 261C/C,
266 T/T on rs67384697). Thus, co-expression of pro-
tective HLA-B and HLA-C alleles as well as of HLA-C
SNPs, and the associated T cell immune responses, some
of which polyfunctional [30], likely provide the strong
and durable control of HIV-1 replication and disease
progression in CASE1.
Additional file
Additional file 1: Table S1. Titer of anti-HIV neutralizing Ab in CASE1’
serum and mucosal-derived fluid. Table S2. Percentage of B lymphocyte
phenotypes in CASE1, her partner, other Elite controllers and HIV-1 negative
controls. Table S3. Peripheral T lymphocyte phenotype distribution (%) in
CASE1 and her partner. Figure S1. CASE1’s HCV related clinical features.
Figure S2. CASE1’s intestinal mucosa histological and ultrastructural analysis.
Figure S3. Amino acid alignments of CASE1 Gag (A) and Env-gp120 (B)
proteins. Figure S4. CXCR4 and CCR5 expression by CASE1’s and partner’s
peripheral blood CD4+ T cells.
Competing interests
All authors declare that they have no competing interests.
Authors’ contributions
All authors contributed to conception and design of the study, acquisition
and analysis of data. All authors contributed in drafting and revising the
manuscript, and approved the final version.
Authors’ information
†James I Mullins, Mauro S Malnati and Massimo Alfano were co-last authors.
Acknowledgments
All authors would like to acknowledge the subject coded as CASE1 for her
repeated willingness to provide biological samples.
This work was supported by the EUROPRISE-Network of Excellence (grant
number LSHP CT-2006-037611 funded by EC under the Sixth Framework
Programme), the NGIN consortium (grant number 201433 and the CombinedHighly Active Anti-Retroviral Microbicides (CHAARM) grant 242135 funded
by EC under the Seventh Framework Programme, the Italian Ministry of
Health (grants 40H16 and 40H23), the Bill and Melinda Gates Foundation
GHRC-CAVD Project, NIH grants to JIM (AI47734) and the Bioinformatics Core
of the University of Washington Centers for AIDS Research (NIH AI27757). We
thank the NIBSC-CFAR (UK) for providing viruses and monoclonal antibodies.
Author details
1Infectious Disease Unit, Busto Arsizio Public Hospital, P.le Solaro n. 3, Busto
Arsizio 21052Varese, Italy. 2Viral Pathogens and Biosafety Unit, Division of
Immunology, Transplantation and Infectious Disease, San Raffaele Scientific
Institute, Milan, Italy. 3Service Lab Fleming Research, Busto Arsizio, Varese,
Italy. 4Human Virology Unit, Division of Immunology, Transplantation and
Infectious Disease, San Raffaele Scientific Institute, Milan, Italy. 5Viral Evolution
and Transmission Unit, Division of Immunology, Transplantation and
Infectious Disease, San Raffaele Scientific Institute, Milan, Italy. 6Department
of Translational Research, Istituto Giannina Gaslini, Genoa, Italy.
7Immunobiology of HIV Unit, Division of Immunology, Transplantation and
Infectious Disease, San Raffaele Scientific Institute, Milan, Italy. 8Pathology
Unit, Luigi Sacco Hospital, Department of Biomedical and Clinical Sciences,
University of Milan, Milan, Italy. 9Departments of Microbiology, Medicine and
Laboratory Medicine, University of Washington, Seattle, WA, USA. 10AIDS
Immunopathogenesis Unit, Division of Immunology, Transplantation and
Infectious Disease, San Raffaele Scientific Institute, Via Olgettina n. 58, Milan
20132, Italy. 11School of Medicine, Vita-Salute San Raffaele University, Milan,
Italy. 12Present address; Division of Experimental Oncology, Unit of Urology,
URI; IRCCS Ospedale San Raffaele, Via Olgettina n. 60, Milan 20132, Italy.
Received: 16 August 2014 Accepted: 20 November 2014References
1. Liu H, Hwangbo Y, Holte S, Lee J, Wang C, Kaupp N, Zhu H, Celum C, Corey L,
McElrath MJ, Zhu T: Analysis of genetic polymorphisms in CCR5, CCR2,
stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular
adhesion molecule-3-grabbing nonintegrin in seronegative individuals
repeatedly exposed to HIV-1. J Infect Dis 2004, 190:1055–1058.
2. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D:
Prevalence and comparative characteristics of long-term nonprogressors
and HIV controller patients in the French Hospital Database on HIV. AIDS
2009, 23:1163–1169.
3. Genovese L, Nebuloni M, Alfano M: Cell-mediated immunity in elite
controllers naturally controlling HIV viral load. Front Immunol 2013, 4:86.
4. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, Asher TE,
Samri A, Schnuriger A, Theodorou I, Costagliola D, Rouzioux C, Agut H,
Marcelin AG, Douek D, Autran B, Appay V: Superior control of HIV-1 replication
by CD8+ T cells is reflected by their avidity, polyfunctionality, and
clonal turnover. J Exp Med 2007, 204:2473–2485.
5. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K,
Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P,
Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J,
Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A,
Goldstein DB: A whole-genome association study of major determinants for
host control of HIV-1. Science 2007, 317:944–947.
6. Guergnon J, Dalmasso C, Broet P, Meyer L, Westrop SJ, Imami N, Vicenzi E,
Morsica G, Tinelli M, Zanone Poma B, Goujard C, Potard V, Gotch FM, Casoli C,
Cossarizza A, Macciardi F, Debre P, Delfraissy JF, Galli M, Autran B, Costagliola D,
Poli G, Theodorou I, Riva A: Single-nucleotide polymorphism-defined class
I and class III major histocompatibility complex genetic subregions
contribute to natural long-term nonprogression in HIV infection. J Infect Dis
2012, 205:718–724.
7. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW,
Churchill M, Di Mascio M, Katlama C, Lafeuillade A, Landay A, Lederman M,
Lewin SR, Maldarelli F, Margolis D, Markowitz M, Martinez-Picado J, Mullins JI,
Mellors J, Moreno S, O'Doherty U, Palmer S, Penicaud MC, Peterlin M, Poli G,
Routy JP, Rouzioux C, Silvestri G, Stevenson M, et al: Towards an HIV cure:
a global scientific strategy. Nat Rev Immunol 2012, 12:607–614.
8. Malnati MS, Scarlatti G, Gatto F, Salvatori F, Cassina G, Rutigliano T, Volpi R,
Lusso P: A universal real-time PCR assay for the quantification of group-M
HIV-1 proviral load. Nat Protoc 2008, 3:1240–1248.
Moroni et al. Journal of Translational Medicine 2014, 12:335 Page 9 of 9
http://www.translational-medicine.com/content/12/1/3359. Grivel JC, Elliott J, Lisco A, Biancotto A, Condack C, Shattock RJ, McGowan I,
Margolis L, Anton P: HIV-1 pathogenesis differs in rectosigmoid and
tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1.
Aids 2007, 21:1263–1272.
10. Nebuloni M, Zawada L, Ferri A, Tosoni A, Zerbi P, Resnati M, Poli G,
Genovese L, Alfano M: HIV-1 infected lymphoid organs upregulate
expression and release of the cleaved form of uPAR that modulates
chemotaxis and virus expression. PLoS One 2013, 8:e70606.
11. Ghezzi S, Pacciarini F, Nozza S, Racca S, Mariani S, Vicenzi E, Lazzarin A,
Veglia F, Tambussi G, Poli G: Persistence of CCR5 usage among primary
human immunodeficiency virus isolates of individuals receiving
intermittent interleukin-2. HIV Med 2010, 11:349–352.
12. Malnati MS, Heltai S, Cosma A, Reitmeir P, Allgayer S, Glashoff RH, Liebrich W,
Vardas E, Imami N, Westrop S, Nozza S, Tambussi G, Butto S, Fanales-Belasio E,
Ensoli B, Ensoli F, Tripiciano A, Fortis C, Lusso P, Poli G, Erfle V, Holmes H:
A new antigen scanning strategy for monitoring HIV-1 specific T-cell
immune responses. J Immunol Methods 2012, 375:46–56.
13. Kutscher S, Dembek CJ, Allgayer S, Heltai S, Stadlbauer B, Biswas P, Nozza S,
Tambussi G, Bogner JR, Stellbrink HJ, Goebel FD, Lusso P, Tinelli M, Poli G,
Erfle V, Pohla H, Malnati M, Cosma A: The intracellular detection of
MIP-1beta enhances the capacity to detect IFN-gamma mediated
HIV-1-specific CD8 T-cell responses in a flow cytometric setting
providing a sensitive alternative to the ELISPOT. AIDS Res Ther 2008, 5:22.
14. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, Yu XG,
Draenert R, Johnston MN, Strick D, Allen TM, Feeney ME, Kahn JO, Sekaly RP,
Levy JA, Rockstroh JK, Goulder PJ, Walker BD: Influence of HLA-B57 on
clinical presentation and viral control during acute HIV-1 infection.
AIDS 2003, 17:2581–2591.
15. Okulicz JF, Lambotte O: Epidemiology and clinical characteristics of elite
controllers. Curr Opin HIV AIDS 2011, 6:163–168.
16. Lazaryan A, Song W, Lobashevsky E, Tang J, Shrestha S, Zhang K, McNicholl
JM, Gardner LI, Wilson CM, Klein RS, Rompalo A, Mayer K, Sobel J, Kaslow
RA: The influence of human leukocyte antigen class I alleles and their
population frequencies on human immunodeficiency virus type 1
control among African Americans. Hum Immunol 2011, 72:312–318.
17. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S,
Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D,
Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J,
Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw
A, Burtt NP, Guiducci C, Gupta N, Gao X, et al: The major genetic
determinants of HIV-1 control affect HLA class I peptide presentation.
Science 2010, 330:1551–1557.
18. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM,
Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M:
HLA B*5701 is highly associated with restriction of virus replication in a
subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci
U S A 2000, 97:2709–2714.
19. Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, Miranda C, Ruiz-Riol
M, Berger CT, Herrero MJ, Palou E, Plana M, Rolland M, Khatri A, Heckerman D,
Pereyra F, Walker BD, Weiner D, Paredes R, Clotet B, Felber BK, Pavlakis GN,
Mullins JI, Brander C: CTL responses of high functional avidity and broad
variant cross-reactivity are associated with HIV control. PLoS One 2012,
7:e29717.
20. Saez-Cirion A, Hamimi C, Bergamaschi A, David A, Versmisse P, Melard A,
Boufassa F, Barre-Sinoussi F, Lambotte O, Rouzioux C, Pancino G: Restriction of
HIV-1 replication in macrophages and CD4+ T cells from HIV controllers.
Blood 2011, 118:955–964.
21. Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, Brumme CJ, Pereyra F,
Kaufmann DE, Trocha A, Block BL, Daar ES, Connick E, Jessen H, Kelleher AD,
Rosenberg E, Markowitz M, Schafer K, Vaida F, Iwamoto A, Little S, Walker
BD: Impaired replication capacity of acute/early viruses in persons who
become HIV controllers. J Virol 2010, 84:7581–7591.
22. Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, McLaughlin M,
Ehler L, Metcalf J, Liu S, Hallahan CW, Connors M: The differential ability of
HLA B*5701+ long-term nonprogressors and progressors to restrict
human immunodeficiency virus replication is not caused by loss of
recognition of autologous viral gag sequences. J Virol 2003, 77:6889–6898.
23. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, Haggerty
CM, Kamireddi AR, Liu Y, Lee J, Persaud D, Gallant JE, Cofrancesco J Jr, Quinn
TC, Wilke CO, Ray SC, Siliciano JD, Nettles RE, Siliciano RF: Residual human i
mmunodeficiency virus type 1 viremia in some patients on antiretroviraltherapy is dominated by a small number of invariant clones rarely found in
circulating CD4+ T cells. J Virol 2006, 80:6441–6457.
24. Bailey JR, Brennan TP, O'Connell KA, Siliciano RF, Blankson JN: Evidence of
CD8+ T-cell-mediated selective pressure on human immunodeficiency
virus type 1 nef in HLA-B*57+ elite suppressors. J Virol 2009, 83:88–97.
25. Salgado M, Brennan TP, O'Connell KA, Bailey JR, Ray SC, Siliciano RF,
Blankson JN: Evolution of the HIV-1 nef gene in HLA-B*57 positive elite
suppressors. Retrovirology 2010, 7:94.
26. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF,
Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong
PD, Shaw GM: Antibody neutralization and escape by HIV-1. Nature 2003,
422:307–312.
27. Migueles SA, Connors M: Long-term nonprogressive disease among
untreated HIV-infected individuals: clinical implications of understanding
immune control of HIV. JAMA 2010, 304:194–201.
28. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, Pollard RB,
Yee HF Jr, Martin JN, Deeks SG, Shacklett BL: Mucosal immune responses to
HIV-1 in elite controllers: a potential correlate of immune control.
Blood 2009, 113:3978–3989.
29. Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG,
Telenti A, Pereyra F, Goldstein D, Wolinsky S, Walker B, Young HA, Carrington
M: Differential microRNA regulation of HLA-C expression and its association
with HIV control. Nature 2011, 472:495–498.
30. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB,
Blankson JN, Siliciano RF: Stimulation of HIV-1-specific cytolytic T lymphocytes
facilitates elimination of latent viral reservoir after virus reactivation. Immunity
2012, 36:491–501.
doi:10.1186/s12967-014-0335-6
Cite this article as: Moroni et al.: Spontaneous control of HIV-1 viremia in a
subject with protective HLA-B plus HLA-C alleles and HLA-C associated single
nucleotide polymorphisms. Journal of Translational Medicine 2014 12:335.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
